ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,618.26
      -0.29%
      US Tech 100
      18,927.60
      -0.06%
      Dow Jones
      41,503.10
      -0.25%
      Brent Oil
      72.545
      0.23%
      Bitcoin
      61,973.30
      0.49%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Krystal Biotech Inc (KRYS) Quote

      Krystal Biotech Inc

      Krystal Biotech Inc (KRYS)

      NASDAQ
      182.74
      -6.52
      (-3.44%)
      Closed September 18 4:00PM
      Delayed by 15 minutes
      184.00
      1.26
      (0.69%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      184.00
      Bid
      182.20
      Ask
      291.38
      Volume
      335,082
      182.185 Day's Range 190.835
      93.95 52 Week Range 219.34
      Market Cap
      5.286B
      Previous Close
      189.26
      Open
      190.02
      Last Trade
      100
      @
      184
      (formt)
      Last Trade Time
      Financial Volume
      $ 62,300,828
      VWAP
      185.9271
      Average Volume (3m)
      274,633
      Shares Outstanding
      28,729,950
      Dividend Yield
      -
      PE Ratio
      480.13
      Earnings Per Share (EPS)
      0.38
      Revenue
      50.7M
      Net Profit
      10.93M

      About Krystal Biotech Inc

      Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.krystalbio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $189.26. Over the last year, Krystal Biotech shares have traded in a share price range of $ 93.95 to $ 219.34.

      Krystal Biotech currently has 28,729,950 shares outstanding. The market capitalization of Krystal Biotech is $5.44 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 480.13.

      Ask ADVFN Intelligence (AI)

      Krystal Biotech (KRYS) Options Flow Summary

      KRYS Options Flow

      Overall Flow

      Bullish

      Net Premium

      34k

      Calls / Puts

      100.00%

      Buys / Sells

      100.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      KRYS Latest News

      More News

      FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

      11 hours ago

      Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

      PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

      September 13 2024
      GlobeNewswire Inc.

      Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

      PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

      September 06 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      August 28 2024
      Edgar (US Regulatory)

      Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

      Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...

      August 28 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 05 2024
      Edgar (US Regulatory)

      Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

      Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study...

      August 05 2024
      GlobeNewswire Inc.

      U.S. Index Futures and Oil Prices Plunge on Recession Concerns

      U.S. index futures fell sharply after a volatile week, with the Nasdaq Composite entering correction territory due to recession concerns and uncertainties about Federal Reserve actions. At 04:37...

      August 05 2024
      IH Market News

      Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

      PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second...

      July 26 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.34-0.722995575699185.34203.285182.69388376194.80359732CS
      4-15.46-7.75092750426199.46206.97181.36223192194.73177479CS
      123.742.07478087207180.26219.34166.905274633193.34016186CS
      2612.397.21985898258171.61219.34144.0001325738179.19468331CS
      5264.4753.9362503137119.53219.3493.95339058152.04502843CS
      156126.05217.51509922357.95219.3438.8563272976110.96067817CS
      260139.1309.79955456644.9219.3431.8922214595.61606853CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		328.97M
      PRTGPortage Biotech Inc
      $ 9.7581
      (115.41%)
      		51.55M
      APLTApplied Therapeutics Inc
      $ 7.86
      (69.03%)
      		51.67M
      XCHXCHG Ltd
      $ 18.40
      (65.77%)
      		1.26M
      WBUYWeBuy Global Ltd
      $ 0.1867
      (60.95%)
      		248.03M
      GLMDGalmed Pharmaceuticals Ltd
      $ 6.83
      (-54.77%)
      		6.24M
      KAKineta Inc
      $ 0.5691
      (-31.35%)
      		530.74k
      DTSSDatasea Inc
      $ 2.07
      (-29.59%)
      		1.34M
      CBUSCibus Inc
      $ 3.595
      (-28.95%)
      		2.31M
      BFIBurgerFi International Inc
      $ 0.1705
      (-26.98%)
      		16.56M
      OMEXOdyssey Marine Exploration Inc
      $ 1.39
      (180.07%)
      		324.51M
      NVDANVIDIA Corporation
      $ 113.37
      (-1.92%)
      		304.66M
      WBUYWeBuy Global Ltd
      $ 0.18675
      (60.99%)
      		228.66M
      SQQQProShares UltraPro Short QQQ
      $ 8.40
      (1.45%)
      		197.87M
      LUNRIntuitive Machines Inc
      $ 7.47
      (38.33%)
      		130.99M

      KRYS Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      KRYS new 52 week high
      👍️0
      Monksdream Monksdream 4 months ago
      KRYS 10Q due 5/6
      👍️0
      Monksdream Monksdream 5 months ago
      KRYS over $30
      👍️0
      Monksdream Monksdream 6 months ago
      KRYS new 52 week high
      👍️0
      Monksdream Monksdream 1 year ago
      From Cathie Wood
      A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
      ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
      Research Associate
      Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

      Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
      👍️0
      wiredawg wiredawg 3 years ago
      Moving nicely today...
      👍️0
      wiredawg wiredawg 3 years ago
      Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
      👍️0
      wiredawg wiredawg 3 years ago
      In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

      👍️0
      wiredawg wiredawg 3 years ago
      30 Nov Tues releases this PR during evening after market close:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
      👍️0
      wiredawg wiredawg 3 years ago
      29 Nov Mon after market closes release this PR:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
      👍️0
      wiredawg wiredawg 3 years ago
      29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

      https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
      👍️0
      wiredawg wiredawg 3 years ago
      This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
      👍️0
      wiredawg wiredawg 3 years ago
      Holding well so far, why the pretty hard drop?
      👍️0
      wiredawg wiredawg 3 years ago
      Why are you surprised? Serious question, not being impudent...
      👍️0
      rynlrt rynlrt 3 years ago
      200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
      👍️0
      Fofo812 Fofo812 3 years ago
      Surprised it held up this long
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Large tutes holdings. Some taking huge gains before years end.
      👍️0
      rynlrt rynlrt 3 years ago
      Not sure this kind of gain is sustainable. May see a big pullback
      👍️0
      Fofo812 Fofo812 3 years ago
      3rd post
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
      👍️0
      Trophy Trophy 5 years ago
      ..
      👍️0

      Your Recent History

      NASDAQ
      KRYS
      Krystal Biotech
      Delayed Upgrade Clock